Evidence map›Paper›PMID 42013016›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy.

Rahmi Atıl Aksoy, Timur Koca, Durmuş Ali Çetmi, Mehmet Kızılkaya, Aylin Fidan Korcum

Abstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rahmi Atıl AksoyDepartment of Radiation Oncology, Izmir City Hospital, Izmir, Turkey.ORCID 0000-0002-5399-5430
Timur KocaDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID 0000-0002-7400-1837
Durmuş Ali ÇetmiDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID 0009-0006-0863-2354
Mehmet KızılkayaDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID 0000-0003-0266-3919
Aylin Fidan KorcumDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID 0000-0003-0318-6122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionThis study aimed to evaluate the independent associations of myopenia, myosteatosis, and frailty with survival outcomes in older patients with prostate cancer undergoing definitive radiotherapy.MethodsA total of 124 patients aged ≥65 years who received definitive radiotherapy for localized or locally advanced prostate cancer between 2014 and 2023 were retrospectively analyzed. Myopenia and myosteatosis were quantified using the psoas muscle index (PMI) and Hounsfield unit average calculation (HUAC), respectively. Comorbidity-based frailty was assessed using the modified frailty index-11 (mFI-11). The cut-off points for the PMI and HUAC were determined using receiver operating characteristic (ROC) curve analysis. Univariate and parsimonious multivariable Cox regression analyses were used to examine the prognostic value of these markers for progression-free survival (PFS) and overall survival (OS).ResultsThe median age of the patients was 72 years (range: 65-87). According to the mFI-11, 47.6% of the patients were classified as frail. The cut-off values for PMI and HUAC were 2.0 cm

Indexed as

FrailtyProstatic NeoplasmsSarcopeniaAgedAged, 80 and overHumansMalePrognosisRetrospective Studiesfrailtymyopeniamyosteatosisprostate cancerradiotherapysurvival

Identifiers

PMID42013016
PMCPMC13111843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.